Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.
about
Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition."NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
P2860
Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Potential of the trifunctional ...... proach of tumor immunotherapy.
@en
type
label
Potential of the trifunctional ...... proach of tumor immunotherapy.
@en
prefLabel
Potential of the trifunctional ...... proach of tumor immunotherapy.
@en
P2093
P2860
P1433
P1476
Potential of the trifunctional ...... pproach of tumor immunotherapy
@en
P2093
Horst Lindhofer
Nina Deppisch
Nina Eissler
Ralph Mocikat
P2860
P2888
P356
10.2119/MOLMED.2012.00140
P407
P577
2013-04-30T00:00:00Z
P5875
P6179
1068965537